Payers’ Guide to New FDA Approvals

Page 1

JUNE 2012

VOLUME 5 I NUMBER 3 I SPECIAL FEATURE

THE PEER-REVIEWED FORUM FOR EVIDENCE IN BENEFIT DESIGN ™

FOR PAYERS, PURCHASERS, POLICYMAKERS, AND OTHER HEALTHCARE STAKEHOLDERS

PAYERS’ GUIDE TO NEW FDA APPROVALS ™

INTRODUCTION: New Drug Approvals in 2011 FDA Approvals of Brand-Name Prescription Drugs in 2011 Ruxolitinib a New Oral Option for Patients with Intermediate- or High-Risk Myelofibrosis Disorders An Overview of Metastatic Castration-Resistant Prostate Cancer and Treatment Tradjenta® (linagliptin) Tablets The 2012 Drug Pipeline

Special Feature

©2012 Engage Healthcare Communications, LLC www.AHDBonline.com


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.